Aldeyra Therapeutics, Inc.
$1.86
+0.71%Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.3).
Valuation inputs: P/E -3.3, earnings yield N/A, momentum +0.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -76.5%, ROIC -59.0%).
Profitability stack: net margin 0.0%, ROE -76.5%, ROIC -59.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +38.6%, momentum +0.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Aldeyra Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Aldeyra Therapeutics, Inc. Fair Value Envelope
No Revenue Data
ALDX has not reported any revenue values in the available annual periods.
Aldeyra Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ALDX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ALDX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ALDX has not reported any net profit margin values in the available annual periods.
Aldeyra Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Aldeyra Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Aldeyra Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that ALDX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 9.67, with estimates ranging from a low of 7.00 to a high of 12.00.
The consensus 1-year price target stands at 9.67, with estimates ranging from a low of 7.00 to a high of 12.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Aldeyra Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $160K and sold $114K worth of ALDX shares, resulting in $46K of net buying activity.
3 Months
75.0K
105.10K
0
0.00
+105K
+$105K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
17.9K
54.71K
22.1K
113.71K
-59K
-$59K
Top Buyers
Douglas Richard
Director
$103K
Alfieri Michael
Officer: Principal Financial Officer
$20K
Phillips Gary M.
Director
$10K
Bronstein Ben
Director
$10K
Walker Neal
Director
$6K
Top Sellers
Machatha Stephen
Officer: Chief Development Officer
$114K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $46K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
ALDX has not reported any dividend yield values in the available annual periods.
aldx Dividend History
Learning Layer
Related Guides
Build conviction on ALDX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.